NEW YORK, Sept. 09, 2021 (Globe NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an revolutionary biopharmaceutical corporation focused on buying, creating and commercializing or monetizing promising biopharmaceutical products and products candidates cost-properly, nowadays announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will take part in a few digital trader conferences in September 2021.
Aspects of the situations are as follows:
H.C. Wainwright 23rd Yearly World-wide Expense Meeting: The company’s presentation will be readily available for on-desire viewing on Fortress’ web site beginning on Monday, September 13, 2021, at 7:00 a.m. ET and will stay accessible on the Events page below the Information & Media section of Fortress’ site:
for around 30 days pursuing the presentation. The firm will participate in one-on-1 conferences throughout the meeting as perfectly.Oppenheimer Drop Health care Everyday living Sciences & MedTech Summit: The enterprise will existing on Monday, September 20, 2021, at 2:55 p.m. ET and will take part in one-on-just one meetings through the convention. A webcast of the presentation will be obtainable on the Events web page under the News & Media part of Fortress’ site:
for close to 30 days subsequent the conference.Cantor World-wide Healthcare Meeting: The firm will present on Tuesday, September 28, 2021, at 3:20 p.m. ET and will take part in just one-on-1 conferences through the conference. A webcast of the presentation will be obtainable on the Gatherings web site less than the News & Media part of Fortress’ web page:
for about 30 days next the conference.
About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an revolutionary biopharmaceutical firm that was ranked in Deloitte’s 2019 and 2020 Technological innovation Rapidly 500™, annual rankings of the quickest-expanding North American organizations in the technological know-how, media, telecommunications, life sciences and energy tech sectors, based mostly on percentages of fiscal year earnings growth around three-yr intervals. Fortress is centered on attaining, acquiring and commercializing higher-potential promoted and enhancement-phase medicines and drug candidates. The business has seven promoted prescription pharmaceutical products and around 25 plans in enhancement at Fortress, at its greater part-owned and the vast majority-controlled partners and at companions it started and in which it holds significant minority possession positions. Such merchandise candidates span 6 large-market locations, which include oncology, uncommon health conditions and gene remedy, which permit it to build value for shareholders. Fortress advancements its diversified pipeline via a streamlined operating composition that fosters effective drug development. The Fortress design is pushed by a earth-course organization improvement crew that is targeted on leveraging its considerable biopharmaceutical industry abilities to additional broaden the company’s portfolio of product or service possibilities. Fortress has founded partnerships with some of the world’s leading academic investigate establishments and biopharmaceutical providers to increase each individual prospect to its whole opportunity, which include Alexion Prescribed drugs, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Investigate Middle, St. Jude Children’s Study Medical center, Nationwide Children’s Healthcare facility and Sentynl Therapeutics, Inc. For far more information, visit www.fortressbiotech.com.
Ahead-Looking Statements This push release may well comprise “forward-seeking statements” in just the this means of Segment 27A of the Securities Act of 1933 and Area 21E of the Securities Exchange Act of 1934, as amended. As used under and during this press launch, the terms “we”, “us” and “our” may possibly refer to Fortress independently or collectively with a single or far more lover organizations, as dictated by context. This kind of statements involve, but are not restricted to, any statements relating to our progress technique and products growth systems and any other statements that are not historical information. Ahead-seeking statements are primarily based on management’s latest anticipations and are subject matter to threats and uncertainties that could negatively have an impact on our business enterprise, working success, fiscal condition and stock cost. Components that could trigger real benefits to vary materially from all those at this time expected consist of: threats relating to our advancement technique our ability to acquire, execute less than and manage funding and strategic agreements and interactions challenges relating to the final results of analysis and advancement activities uncertainties relating to preclinical and clinical tests pitfalls relating to the timing of beginning and completing scientific trials our dependence on 3rd-bash suppliers risks relating to the COVID-19 outbreak and its probable effect on our employees’ and consultants’ means to comprehensive work in a well timed manner and on our ability to obtain more funding on favorable phrases or at all our means to catch the attention of, combine and keep vital personnel the early phase of merchandise underneath improvement our want for significant additional cash government regulation patent and intellectual home issues competition as well as other challenges explained in our SEC filings. We expressly disclaim any obligation or enterprise to release publicly any updates or revisions to any forward-wanting statements contained herein to mirror any improve in our anticipations or any modifications in activities, disorders or instances on which any this sort of statement is primarily based, besides as may possibly be demanded by regulation, and we claim the defense of the risk-free harbor for forward-looking statements contained in the Personal Securities Litigation Reform Act of 1995. The information contained herein is meant to be reviewed in its totality, and any stipulations, disorders or provisos that utilize to a provided piece of details in just one part of this push release need to be examine as applying mutatis mutandis to each other occasion of these types of details showing up herein.
Organization Contacts: Jaclyn Jaffe and William Begien Fortress Biotech, Inc. (781) 652-4500 [email protected]
Trader Relations Make contact with: Daniel Ferry LifeSci Advisors, LLC (617) 430-7576 [email protected]
Media Relations Make contact with: Tony Plohoros 6 Levels (908) 591-2839 [email protected]
Copyright 2021 GlobeNewswire, Inc.
